Zogenix soars on FDA Zohydro OK; 1st single-entity hydrocodone
This article was originally published in Scrip
Executive Summary
Shares of Zogenix rocketed as high as 54% on 25 October after the US FDA OK'd the company's Zohydro ER (hydrocodone bitartrate extended-release capsules) as the first single-entity, extended-release hydrocodone product approved in the US to manage pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.